Helus Pharma™ Announces US$50 Million Underwritten Offering

Article content

NEW YORK and TORONTO, June 24, 2026 (GLOBE NEWSWIRE) — Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), is pleased to announce the pricing of an underwritten offering of 10,309,280 common shares in the capital of the Company (the “Common Shares”) at an offering price of US$4.85 per Common Share, for aggregate gross proceeds of US$50 million (the “Offering”).

Article content

Article content

Cantor and Barclays are acting as joint bookrunning managers for the Offering. Bloom Burton Securities Inc. and Lucid Capital Markets are acting as lead managers for the Offering.

Article content

Article content

Article content

The Offering is expected to close on June 25, 2026 or such other date as may be mutually agreed by the Company and the underwriters. The Offering is subject to customary closing conditions, including approval of Cboe Canada Inc. (“Cboe Canada”) and notification of the Offering to the Nasdaq Global Market (the “Nasdaq”).

Article content

The Company intends to use the net proceeds from the Offering to progress the Company’s HLP003 for major depressive disorder with Phase 3 APPROACH data expected in the fourth quarter of 2026, HLP004 for generalized anxiety disorder, and HLP005 programs, and for working capital and general corporate purposes.

Article content

The Company is offering the Common Shares only in the United States and in certain other jurisdictions outside of Canada, pursuant to a prospectus supplement (the “Prospectus Supplement”) to the Company’s short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025 (the “Base Shelf Prospectus”). The Prospectus Supplement will be filed with the securities commissions in all of the provinces and territories of Canada and with the United States Securities and Exchange Commission (the “SEC”), as part of a registration statement on Form F-10 (File No. 333-292294) which was filed with the SEC, under the United States Securities Act of 1933, as amended, on December 19, 2025, in accordance with the Multijurisdictional Disclosure System established between Canada and the United States. Prior to forming an investment decision, prospective investors should read the Base Shelf Prospectus and the documents incorporated by reference therein, including any marketing materials, which will be available on the Company’s SEDAR+ profile at www.sedarplus.ca and the Company’s EDGAR profile at www.sec.gov/edgar.

Article content

Article content

The Base Shelf Prospectus is, and the Prospectus Supplement will be accessible on SEDAR+ and on EDGAR. An electronic or paper copy of the Base Shelf Prospectus and the Prospectus Supplement, upon filing, and any amendments thereto, may be obtained, without charge, from any of the Representatives by contacting Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, New York 10022, or by email at [email protected], or Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, via telephone at (888) 603-5847, or via e-mail at [email protected].

Article content

This news release does not constitute an offer to sell or the solicitation of an offer to buy securities, nor will there be any sale of the securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Article content

About
Helus Pharma

Article content

Helus Pharma™, the commercial operating name of Cybin Inc., is a clinical stage pharmaceutical company committed to helping minds heal by developing proprietary NSAs – novel serotonergic agonists: synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. The Company’s proprietary NSAs are intended to address the large unmet need for people who suffer from depression, anxiety, and other mental health conditions.